A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Completed · Phase 1
Conditions studied: Advanced Cancer
In brief
The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.
Key facts
- Study ID
- NCT04148937
- Run by
- Eli Lilly and Company
- People needed
- 52
- Starts
- 2020-01-16
- Expected to finish
- 2022-06-20
- Last updated by the study team
- 2024-04-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer
- Participants must have stopped other forms of treatment for the cancer
- In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study
- Participants must not be pregnant, and must agree to use birth control
- Participants must have progressed through or be intolerant to therapies with known clinical benefit
You may not qualify if…
- Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids
- Participant must not have cancer that has spread to the brain
- Participant must not have received a vaccine within the last 30 days
- Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery
- Participant must not have an infection that is currently being treated
Where it is running
- Sarah Cannon Research Institute at HealthOne — Denver, Colorado, United States
- Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida, United States
- START Midwest — Grand Rapids, Michigan, United States
- Washington University Medical School — St Louis, Missouri, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- Sarah Cannon Research Institute SCRI — Nashville, Tennessee, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Addenbrookes Hospital — Cambridge, Cambridgeshire, United Kingdom
- Beatson West of Scotland Cancer Center — Glasgow, Scotland, United Kingdom
- Christie NHS Foundation Trust — Manchester, United Kingdom
- Royal Marsden NHS Trust — Sutton, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.